COVID‐19: Herd immunity and convalescent plasma transfer therapy
2020; Wiley; Volume: 92; Issue: 9 Linguagem: Inglês
10.1002/jmv.25870
ISSN1096-9071
Autores Tópico(s)COVID-19 epidemiological studies
ResumoJournal of Medical VirologyVolume 92, Issue 9 p. 1380-1382 COMMENTARY COVID-19: Herd immunity and convalescent plasma transfer therapy Kirtimaan Syal PhD, PGDMLE, Corresponding Author Kirtimaan Syal PhD, PGDMLE [email protected] orcid.org/0000-0002-0046-0205 Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, Tennessee Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin Correspondence Kirtimaan Syal, PhD, PGDMLE, Scientist, Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, TN 38105. Email: [email protected]Search for more papers by this author Kirtimaan Syal PhD, PGDMLE, Corresponding Author Kirtimaan Syal PhD, PGDMLE [email protected] orcid.org/0000-0002-0046-0205 Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, Tennessee Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin Correspondence Kirtimaan Syal, PhD, PGDMLE, Scientist, Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, TN 38105. Email: [email protected]Search for more papers by this author First published: 13 April 2020 https://doi.org/10.1002/jmv.25870Citations: 53Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020: 1-4. PubMedWeb of Science®Google Scholar 2Liu Y, Gayle AA, Wilder-Smith A, Rocklov J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020; 27(2): 1-4. 10.1093/jtm/taaa021 CASWeb of Science®Google Scholar 3Heffernan JM, Smith RJ, Wahl LM. Perspectives on the basic reproductive ratio. J R Soc Interface. 2005; 2(4): 281-293. 10.1098/rsif.2005.0042 CASPubMedWeb of Science®Google Scholar 4Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infect Dis. 2014; 14: 480. 10.1186/1471-2334-14-480 PubMedWeb of Science®Google Scholar 5Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109:102433. 10.1016/j.jaut.2020.102433 CASPubMedWeb of Science®Google Scholar 6Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nature Med. 2020. Web of Science®Google Scholar 7Fine P, Eames K, Heymann DL. "Herd immunity": a rough guide. Clin Infect Dis. 2011; 52(7): 911-916. 10.1093/cid/cir007 PubMedWeb of Science®Google Scholar 8Joseph G. Can you get coronavirus twice? The Hill. 2020. Google Scholar 9An J, Liao X, Xiao T. Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test. medRxiv. 2020. PubMedGoogle Scholar 10Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016; 14(2): 152-157. PubMedWeb of Science®Google Scholar 11Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020. 10.1001/jama.2020.4783 PubMedWeb of Science®Google Scholar 12Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Nat Acad Sci. 2020. 10.1073/pnas.2004168117 Web of Science®Google Scholar 13Kathleen M. Johns Hopkins gets FDA approval to test blood plasma therapy to treat COVID-19 patients. John Hopkins Web. 2020. https://hub.jhu.edu/2020/04/03/blood-plasma-sera-covid-19-fda-approval/ Google Scholar 14Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020. 10.1001/jama.2020.4940 PubMedWeb of Science®Google Scholar 15Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020; 20(4): 398-400. 10.1016/S1473-3099(20)30141-9 CASPubMedWeb of Science®Google Scholar 16 FDA. Investigational COVID-19 convalescent plasma—emergency INDs. US Food and Drug Administration. 2020. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds Google Scholar 17Brown JF, Dye JM, Tozay S, et al. Anti-Ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with Ebola virus disease. J Infect Dis. 2018; 218(4): 555-562. 10.1093/infdis/jiy199 CASPubMedWeb of Science®Google Scholar 18Molina JM, Delaugerre C, Goff JL, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Médecine et Maladies Infectieuses. 2020. 10.1016/j.medmal.2020.03.006 Web of Science®Google Scholar 19Lu CC, Chen MY, Chang YL. Potential therapeutic agents against COVID-19: what we know so far. J Chin Med Assoc. 2020. Web of Science®Google Scholar Citing Literature Volume92, Issue9Special Issue on New coronavirus (2019‐nCoV or SARS‐CoV‐2) and the outbreak of the respiratory illness (COVID‐19): Part‐VSeptember 2020Pages 1380-1382 ReferencesRelatedInformation
Referência(s)